Finance

Biopharmaceutical company reports year-end and fourth quarter results

Published in Vaccine Weekly, March 16th, 2005

Nabi Biopharmaceuticals (NABI) announced that biopharmaceutical sales for 2004 were at a record level of $131.8 million compared to $109.5 million for 2003, an increase of 20%.

This drove the full-year gross margin earned on sales in 2004 to a record 48% of sales or $85.8 million, compared to $76.8 million or 44% of sales for 2003.

The higher margin on biopharmaceutical sales funded an unprecedented level of clinical and research achievement, including filing for licensure of three products in Europe: StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine), PhosLo (calcium acetate) and Nabi-HB Intravenous [hepatitis B Immune Globulin...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-03-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry